← Back to Screener
Rapport Therapeutics, Inc. Common Stock (RAPP)
Price$36.10
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)13.58%
Price vs S&P 500 (4W)-5.09%
VGM Score78.53
Market Capitalization$1.73B
All Metrics
Book Value / Share (Quarterly)$9.86
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.69
Price vs S&P 500 (YTD)10.83%
EPS (TTM)$-2.60
10-Day Avg Trading Volume0.26M
EPS Excl Extra (TTM)$-2.60
EPS (Annual)$-2.86
ROI (Annual)-23.00%
Cash / Share (Quarterly)$9.97
ROA (Last FY)-21.76%
EBITD / Share (TTM)$-2.89
Cash Flow / Share (Annual)$-1.84
P/B Ratio3.66x
P/B Ratio (Quarterly)3.17x
Net Income / Employee (Annual)$-1,327,200
Net Interest Coverage (TTM)-36.38x
ROA (TTM)-23.44%
EPS Incl Extra (Annual)$-2.86
Current Ratio (Annual)26.17x
Quick Ratio (Quarterly)26.65x
3-Month Avg Trading Volume0.33M
52-Week Price Return192.78%
Revenue / Employee (TTM)$0
52-Week High$42.27
EPS Excl Extra (Annual)$-2.86
26-Week Price Return21.51%
Quick Ratio (Annual)25.76x
13-Week Price Return21.75%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)27.08x
Enterprise Value$1.65B
Revenue / Employee (Annual)$0
Cash / Share (Annual)$10.27
3-Month Return Std Dev59.22%
Net Income / Employee (TTM)$-1,277,100
ROE (Last FY)-23.00%
EPS Basic Excl Extra (Annual)$-2.86
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.60
ROI (TTM)-24.79%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)168.42%
Year-to-Date Return18.98%
5-Day Price Return-2.72%
EPS Normalized (Annual)$-2.86
Month-to-Date Return-8.61%
EBITD / Share (Annual)$-3.19
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.60
P/B Ratio (Annual)2.98x
Book Value / Share (Annual)$10.14
Price vs S&P 500 (13W)13.50%
Beta3.04x
Revenue / Share (TTM)$0.00
ROE (TTM)-24.79%
52-Week Low$10.51
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.42est. -0.68
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.27
4.25
4.25
4.29
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RAPPRapport Therapeutics, Inc. Common Stock | — | — | B | $36.10 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Rapport Therapeutics is a clinical-stage biotechnology company developing small-molecule precision medicines for neurological and psychiatric disorders. Its lead program, RAP-219, is in clinical development for focal onset seizures, generalized tonic-clonic seizures, and bipolar mania. The company also maintains two discovery-stage nicotinic acetylcholine receptor programs targeting chronic pain and hearing disorders.